Barclays PLC Raises Stock Position in Achieve Life Sciences, Inc. (NASDAQ:ACHV)

Barclays PLC lifted its position in Achieve Life Sciences, Inc. (NASDAQ:ACHV) by 303.1% in the third quarter, according to its most recent Form 13F filing with the SEC. The firm owned 47,655 shares of the biopharmaceutical company’s stock after purchasing an additional 35,832 shares during the period. Barclays PLC owned 0.14% of Achieve Life Sciences worth $226,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors also recently bought and sold shares of ACHV. Bank of New York Mellon Corp bought a new stake in shares of Achieve Life Sciences in the second quarter valued at about $482,000. Rhumbline Advisers purchased a new position in Achieve Life Sciences during the 2nd quarter valued at about $197,000. State Street Corp raised its holdings in shares of Achieve Life Sciences by 6.8% in the 3rd quarter. State Street Corp now owns 431,520 shares of the biopharmaceutical company’s stock valued at $2,045,000 after purchasing an additional 27,419 shares in the last quarter. Verition Fund Management LLC bought a new stake in shares of Achieve Life Sciences in the 3rd quarter valued at about $113,000. Finally, The Manufacturers Life Insurance Company purchased a new stake in shares of Achieve Life Sciences in the 2nd quarter worth approximately $69,000. Institutional investors own 33.52% of the company’s stock.

Achieve Life Sciences Price Performance

Shares of NASDAQ:ACHV opened at $3.55 on Tuesday. Achieve Life Sciences, Inc. has a twelve month low of $3.42 and a twelve month high of $5.59. The company has a current ratio of 6.78, a quick ratio of 6.78 and a debt-to-equity ratio of 0.31. The company has a market cap of $122.08 million, a PE ratio of -3.14 and a beta of 1.66. The company’s 50 day moving average is $4.27 and its 200 day moving average is $4.52.

Achieve Life Sciences (NASDAQ:ACHV) last announced its quarterly earnings results on Thursday, November 7th. The biopharmaceutical company reported ($0.36) earnings per share for the quarter, missing the consensus estimate of ($0.26) by ($0.10). During the same period in the prior year, the business earned ($0.34) earnings per share. On average, sell-side analysts forecast that Achieve Life Sciences, Inc. will post -1.17 EPS for the current year.

Analyst Ratings Changes

Several research firms have recently commented on ACHV. RODMAN&RENSHAW raised Achieve Life Sciences to a “strong-buy” rating in a research report on Thursday, November 14th. Raymond James began coverage on shares of Achieve Life Sciences in a report on Friday, September 27th. They issued a “strong-buy” rating and a $20.00 target price for the company. Finally, Rodman & Renshaw began coverage on shares of Achieve Life Sciences in a report on Thursday, November 14th. They issued a “buy” rating and a $12.00 price target on the stock. Four equities research analysts have rated the stock with a buy rating and two have given a strong buy rating to the company’s stock. According to MarketBeat.com, Achieve Life Sciences has a consensus rating of “Buy” and a consensus target price of $14.80.

About Achieve Life Sciences

Achieve Life Sciences, Inc, a clinical-stage pharmaceutical company, develops and commercializes cytisinicline for smoking cessation and nicotine addiction. The company offers cytisinicline, a plant-based alkaloid that interacts with nicotine receptors in the brain that reduce the severity of nicotine withdrawal symptoms.